{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:16:55Z","timestamp":1791958615166,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["96013030675"],"award-info":[{"award-number":["96013030675"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic sclerosis (SSc) or scleroderma is a multiorgan rheumatoid disease characterized by skin tightening or organ dysfunction due to fibrosis, vascular damage, and autoimmunity. No specific cause has been discovered for this illness, and hence no effective treatment exists for it. On the other hand, due to the lack of diagnostic biomarkers capable of effectively and specifically differentiating the patients, early diagnosis has not been possible. Due to their potent regulatory roles in molecular pathways, microRNAs are among the novel candidates for the diagnosis and treatment of diseases like SSc. MiR-27a is a microRNA known for its role in the pathogenesis of fibrosis and cancer, both of which employ similar signaling pathways; hence we hypothesized that Mir-27a could be dysregulated in the blood of individuals affected by SSc and it might be useful in the diagnosis or treatment of this disease. Blood was collected from 60 SSc patients (30 limited and 30 diffuse) diagnosed by a rheumatologist according to ACR\/AULAR criteria; following RNA isolation and cDNA synthesis; real-time qPCR was performed on the samples using Taq-Man probes and data were analyzed by the \u0394\u0394CT method. Also, potential targets of miR-27a were evaluated using bioinformatics. It was revealed that miR-27a was significantly down-regulated in SSc patients in comparison to healthy individuals, but there was no difference in miR-27 expression between limited and diffused SSc patients. Besides, miR-27a was found to target several contributing factors to SSc. It seems that miR-27a has a protective role in SSc, and its downregulation could result in the disease's onset. Based on bioinformatics analyses, it is speculated that miR-27a likely targets factors contributing to the pathogenesis of SSc, which are elevated upon the downregulation of miR-27a; hence, miR-27a mimics could be considered as potential therapeutic agents for the treatment of SSc in future studies. Since no difference was observed between limited and diffuse patient groups, it is unlikely that this microRNA has a role in disease progression. According to ROC analysis of qPCR data, miR-27a could be employed as a valuable diagnostic biomarker for SSc.<\/jats:p>","DOI":"10.1038\/s41598-022-23723-7","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T17:05:36Z","timestamp":1667840736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Paria","family":"Bayati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Ali","family":"Assarehzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Poormoghim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-9483","authenticated-orcid":false,"given":"Nazanin","family":"Mojtabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"issue":"4","key":"23723_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5114\/reum.2019.87619","volume":"57","author":"P Sobolewski","year":"2019","unstructured":"Sobolewski, P. et al. Systemic sclerosis\u2014multidisciplinary disease: Clinical features and treatment. Reumatologia 57(4), 221\u2013233 (2019).","journal-title":"Reumatologia"},{"key":"23723_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/acr.24076","volume":"72","author":"K Morrisroe","year":"2019","unstructured":"Morrisroe, K. et al. Incidence, risk factors and outcomes of cancer in systemic sclerosis. Arthritis Care Res. 72, 1625\u20131635 (2019).","journal-title":"Arthritis Care Res."},{"issue":"11","key":"23723_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fernandez-Codina","year":"2018","unstructured":"Fernandez-Codina, A., Walker, K. M. & Pope, J. E. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 70(11), 1820\u20131828 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"23723_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/CLEP.S191418","volume":"11","author":"A Bergamasco","year":"2019","unstructured":"Bergamasco, A., Hartmann, N., Wallace, L. & Verpillat, P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin. Epidemiol. 11, 257\u2013273 (2019).","journal-title":"Clin. Epidemiol."},{"key":"23723_CR5","unstructured":"Tsou, P. S., Varga, J. & O'Reilly, S. A.-O. Advances in Epigenetics in Systemic Sclerosis: Molecular Mechanisms and Therapeutic Potential. (1759\u20134804 (Electronic))."},{"issue":"1","key":"23723_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-016-0929-x","volume":"18","author":"S O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly, S. MicroRNAs in fibrosis: Opportunities and challenges. Arthritis Res. Ther. 18(1), 11 (2016).","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"23723_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102396","volume":"18","author":"TW Henry","year":"2019","unstructured":"Henry, T. W., Mendoza, F. A. & Jimenez, S. A. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmun. Rev. 18(11), 102396 (2019).","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"23723_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/1756-185X.13924","volume":"23","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Wu, H., Zhao, M. & Lu, Q. Meta-analysis of differentially expressed microRNAs in systemic sclerosis. Int. J. Rheum. Dis. 23(10), 1297\u20131304 (2020).","journal-title":"Int. J. Rheum. Dis."},{"issue":"11","key":"23723_CR9","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 65(11), 2737\u20132747 (2013).","journal-title":"Arthritis Rheum."},{"key":"23723_CR10","first-page":"52","volume-title":"Very Early and Early Diagnosis of Systemic Sclerosis. Novel Insights into Systemic Sclerosis Management","author":"G Lepri","year":"2013","unstructured":"Lepri, G., Randone, S. B., Bruni, C., Matucci-Cerinic, M. & Guiducci, S. Very Early and Early Diagnosis of Systemic Sclerosis. Novel Insights into Systemic Sclerosis Management 52\u201360 (Future Medicine Ltd, 2013)."},{"issue":"11","key":"23723_CR11","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.3390\/jcm9113388","volume":"9","author":"A Utsunomiya","year":"2020","unstructured":"Utsunomiya, A., Oyama, N. & Hasegawa, M. Potential biomarkers in systemic sclerosis: A literature review and update. J. Clin. Med. 9(11), 3388 (2020).","journal-title":"J. Clin. Med."},{"issue":"2","key":"23723_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/cells9020276","volume":"9","author":"CE Condrat","year":"2020","unstructured":"Condrat, C. E. et al. miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells 9(2), 276 (2020).","journal-title":"Cells"},{"issue":"11","key":"23723_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.bbamcr.2010.06.013","volume":"1803","author":"F Wahid","year":"2010","unstructured":"Wahid, F., Shehzad, A., Khan, T. & Kim, Y. Y. MicroRNAs: Synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 1803(11), 1231\u201343 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"23723_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O'Brien","year":"2018","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y. & Peng, C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. 9, 402 (2018).","journal-title":"Front. Endocrinol."},{"issue":"1","key":"23723_CR15","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng, Y. & Croce, C. M. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 1(1), 15004 (2016).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"23723_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-6-15","volume":"6","author":"T Papagiannakopoulos","year":"2008","unstructured":"Papagiannakopoulos, T. & Kosik, K. S. MicroRNAs: Regulators of oncogenesis and stemness. BMC Med. 6(1), 15 (2008).","journal-title":"BMC Med."},{"issue":"1","key":"23723_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1741-7015-11-168","volume":"11","author":"JF Brothers","year":"2013","unstructured":"Brothers, J. F. et al. Bridging the clinical gaps: Genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med. 11(1), 168 (2013).","journal-title":"BMC Med."},{"issue":"1","key":"23723_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1423-0127-20-99","volume":"20","author":"KKW To","year":"2013","unstructured":"To, K. K. W. MicroRNA: A prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J. Biomed. Sci. 20(1), 99 (2013).","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"23723_CR19","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.7150\/jca.31361","volume":"10","author":"X Li","year":"2019","unstructured":"Li, X., Xu, M., Ding, L. & Tang, J. MiR-27a: A novel biomarker and potential therapeutic target in tumors. J. Cancer 10(12), 2836\u20132848 (2019).","journal-title":"J. Cancer"},{"issue":"1","key":"23723_CR20","doi-asserted-by":"publisher","first-page":"13891","DOI":"10.1038\/s41598-019-50210-3","volume":"9","author":"A Kulyt\u00e9","year":"2019","unstructured":"Kulyt\u00e9, A. et al. MicroRNA-27a\/b-3p and PPARG regulate SCAMP3 through a feed-forward loop during adipogenesis. Sci. Rep. 9(1), 13891 (2019).","journal-title":"Sci. Rep."},{"issue":"1","key":"23723_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12860-016-0123-7","volume":"18","author":"X Zeng","year":"2017","unstructured":"Zeng, X., Huang, C., Senavirathna, L., Wang, P. & Liu, L. miR-27b inhibits fibroblast activation via targeting TGF\u03b2 signaling pathway. BMC Cell Biol. 18(1), 9 (2017).","journal-title":"BMC Cell Biol."},{"issue":"3","key":"23723_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41419-018-0431-2","volume":"9","author":"F Fang","year":"2018","unstructured":"Fang, F. et al. miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-\u03b2RI signaling pathway. Cell Death Dis. 9(3), 395 (2018).","journal-title":"Cell Death Dis."},{"issue":"8","key":"23723_CR23","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/mc.22655","volume":"56","author":"D-K Chae","year":"2017","unstructured":"Chae, D.-K. et al. MIR-27a regulates the TGF-\u03b2 signaling pathway by targeting SMAD2 and SMAD4 in lung cancer. Mol. Carcinog. 56(8), 1992\u20131998 (2017).","journal-title":"Mol. Carcinog."},{"issue":"9","key":"23723_CR24","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1681\/ASN.2016111213","volume":"28","author":"B Wang","year":"2017","unstructured":"Wang, B. et al. MicroRNA-23a and MicroRNA-27a mimic exercise by ameliorating CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 28(9), 2631 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"23723_CR25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/j.1742-4658.2009.06967.x","volume":"276","author":"Q Lin","year":"2009","unstructured":"Lin, Q., Gao, Z., Alarcon, R. M., Ye, J. & Yun, Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 276(8), 2348\u20132358 (2009).","journal-title":"FEBS J."},{"issue":"12","key":"23723_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/onc.2012.171","volume":"32","author":"C Freudlsperger","year":"2013","unstructured":"Freudlsperger, C. et al. TGF-beta and NF-kappaB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 32(12), 1549\u20131559 (2013).","journal-title":"Oncogene"},{"issue":"2","key":"23723_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/ijmm.2017.3021","volume":"40","author":"B Zhou","year":"2017","unstructured":"Zhou, B., Li, H. & Shi, J. miR27 inhibits the NF-kappaB signaling pathway by targeting leptin in osteoarthritic chondrocytes. Int. J. Mol. Med. 40(2), 523\u2013530 (2017).","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"23723_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1165\/rcmb.2015-0205OC","volume":"54","author":"H Cui","year":"2016","unstructured":"Cui, H. et al. MicroRNA-27a-3p is a negative regulator of lung fibrosis by targeting myofibroblast differentiation. Am. J. Respir. Cell Mol. Biol. 54(6), 843\u2013852 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"23723_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/039463200902200303","volume":"22","author":"B Marasini","year":"2009","unstructured":"Marasini, B., Conciato, L., Belloli, L. & Massarotti, M. Systemic sclerosis and cancer. Int. J. Immunopathol. Pharmacol. 22(3), 573\u2013578 (2009).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"23723_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13075-018-1630-z","volume":"20","author":"B Korman","year":"2018","unstructured":"Korman, B. et al. Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis. Arthritis Res. Ther. 20(1), 145 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"23723_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrrheum.2016.223","volume":"13","author":"J Varga","year":"2017","unstructured":"Varga, J. & Marangoni, R. G. Dermal white adipose tissue implicated in SSc pathogenesis. Nat. Rev. Rheumatol. 13, 71 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"23723_CR32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/exd.12256","volume":"22","author":"S Ohgo","year":"2013","unstructured":"Ohgo, S. et al. Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF-beta1. Exp. Dermatol. 22(11), 769\u2013771 (2013).","journal-title":"Exp. Dermatol."},{"key":"23723_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1874312901206010130","volume":"6","author":"S Vettori","year":"2012","unstructured":"Vettori, S., Gay, S. & Distler, O. Role of MicroRNAs in fibrosis. Open Rheumatol. J. 6, 130\u2013139 (2012).","journal-title":"Open Rheumatol. J."},{"issue":"1","key":"23723_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/exd.14136","volume":"30","author":"J Henderson","year":"2021","unstructured":"Henderson, J., Pryzborski, S., Stratton, R. & O\u2019Reilly, S. Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p. Exp. Dermatol. 30(1), 162\u2013168 (2021).","journal-title":"Exp. Dermatol."},{"issue":"2","key":"23723_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/2397198318809224","volume":"4","author":"Y Allanore","year":"2019","unstructured":"Allanore, Y. et al. Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. J. Scleroderma Relat. Disord. 4(2), 149\u2013159 (2019).","journal-title":"J. Scleroderma Relat. Disord."},{"issue":"1","key":"23723_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22631\/rr.2020.69997.1083","volume":"5","author":"M Asgari","year":"2020","unstructured":"Asgari, M. et al. Evaluation of Autoantibodies in patients with Systemic Sclerosis. Rheumatol. Res. 5(1), 1\u20136 (2020).","journal-title":"Rheumatol. Res."},{"issue":"8","key":"23723_CR37","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00296-013-2668-5","volume":"33","author":"H Poormoghim","year":"2013","unstructured":"Poormoghim, H. et al. Systemic sclerosis: Demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int. 33(8), 1943\u20131950 (2013).","journal-title":"Rheumatol Int."},{"issue":"8","key":"23723_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/gene.2012.45","volume":"13","author":"S Min","year":"2012","unstructured":"Min, S. et al. TGF-\u03b2-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun. 13(8), 621\u2013631 (2012).","journal-title":"Genes Immun."},{"issue":"8","key":"23723_CR39","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/mc.22655","volume":"56","author":"DK Chae","year":"2017","unstructured":"Chae, D. K. et al. MIR-27a regulates the TGF-\u03b2 signaling pathway by targeting SMAD2 and SMAD4 in lung cancer. Mol. Carcinog. 56(8), 1992\u20131998 (2017).","journal-title":"Mol. Carcinog."},{"key":"23723_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110697","volume":"503","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Zhang, X., An, Y., Liu, B. & Lu, M. LncRNA HCP5 promotes cell proliferation and inhibits apoptosis via miR-27a-3p\/IGF-1 axis in human granulosa-like tumor cell line KGN. Mol. Cell. Endocrinol. 503, 110697 (2020).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"23723_CR41","first-page":"2307","volume":"19","author":"W Zhang","year":"2019","unstructured":"Zhang, W., Chen, L., Geng, J., Liu, L. & Xu, L. \u03b2-elemene inhibits oxygen-induced retinal neovascularization via promoting miR-27a and reducing VEGF expression. Mol Med Rep. 19(3), 2307\u20132316 (2019).","journal-title":"Mol Med Rep."},{"issue":"5","key":"23723_CR42","first-page":"485","volume":"17","author":"I Elahe","year":"2018","unstructured":"Elahe, I. et al. Effect of progesterone on expression of MMP7 and MMP13 in lungs of female mice. Iran. J. Allergy Asthma Immunol. 17(5), 485\u2013489 (2018).","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"4","key":"23723_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2022.110391","volume":"114","author":"Q Cheng","year":"2022","unstructured":"Cheng, Q. et al. MicroRNA-27a-3p inhibits lung and skin fibrosis of systemic sclerosis by negatively regulating SPP1. Genomics 114(4), 110391 (2022).","journal-title":"Genomics"},{"key":"23723_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fonc.2019.00893","volume":"9","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. MicroRNA-27a (miR-27a) in solid tumors: A review based on mechanisms and clinical observations. Front. Oncol. 9, 893 (2019).","journal-title":"Front. Oncol."},{"issue":"8","key":"23723_CR45","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/mc.22655","volume":"56","author":"DK Chae","year":"2017","unstructured":"Chae, D. K. et al. MIR-27a regulates the TGF-beta signaling pathway by targeting SMAD2 and SMAD4 in lung cancer. Mol. Carcinog. 56(8), 1992\u20131998 (2017).","journal-title":"Mol. Carcinog."},{"issue":"10","key":"23723_CR46","doi-asserted-by":"publisher","first-page":"e0186718","DOI":"10.1371\/journal.pone.0186718","volume":"12","author":"Q Xu","year":"2017","unstructured":"Xu, Q. et al. miR-27a induced by colon cancer cells in HLECs promotes lymphangiogenesis by targeting SMAD4. PLoS ONE 12(10), e0186718 (2017).","journal-title":"PLoS ONE"},{"issue":"10","key":"23723_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/kjm2.12092","volume":"35","author":"X-L Zhang","year":"2019","unstructured":"Zhang, X.-L., An, B.-F. & Zhang, G.-C. MiR-27 alleviates myocardial cell damage induced by hypoxia\/reoxygenation via targeting TGFBR1 and inhibiting NF-\u03baB pathway. Kaohsiung J. Med. Sci. 35(10), 607\u2013614 (2019).","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"1","key":"23723_CR48","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.18632\/oncotarget.23262","volume":"9","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. Oncotarget 9(1), 1075\u20131090 (2017).","journal-title":"Oncotarget"},{"issue":"8","key":"23723_CR49","doi-asserted-by":"publisher","first-page":"e0221077","DOI":"10.1371\/journal.pone.0221077","volume":"14","author":"SY Jang","year":"2019","unstructured":"Jang, S. Y., Chae, M. K., Lee, J. H., Lee, E. J. & Yoon, J. S. MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves\u2019 orbitopathy. PLoS ONE 14(8), e0221077 (2019).","journal-title":"PLoS ONE"},{"key":"23723_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2019.106393","volume":"71","author":"K Deng","year":"2020","unstructured":"Deng, K. et al. miR-27a is an important adipogenesis regulator associated with differential lipid accumulation between intramuscular and subcutaneous adipose tissues of sheep. Domest. Anim. Endocrinol. 71, 106393 (2020).","journal-title":"Domest. Anim. Endocrinol."},{"issue":"4","key":"23723_CR51","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jcsm.12296","volume":"9","author":"A Zhang","year":"2018","unstructured":"Zhang, A. et al. miRNA-23a\/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk. J. Cachexia. Sarcopenia Muscle 9(4), 755\u2013770 (2018).","journal-title":"J. Cachexia. Sarcopenia Muscle"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23723-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T06:10:40Z","timestamp":1668060640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23723"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23723-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"20 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18932"}}